# Merck & Company, Inc.

Type: Company (MRK)

Source: AI Intelligence Brief — https://getaibrief.com/entity/merck-company-inc
Canonical HTML page: https://getaibrief.com/entity/merck-company-inc

## Timeline

- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2025-09**: Merck exercises EVX-B3 option — Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.

## Recent coverage (1 stories)

### Merck's 1.21M-Share Stake Backs AI Vaccine Discovery
2026-08-22 13:50:16 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's stake in Evaxion is a small but meaningful validation that AI can identify viable vaccine antigens. For AI researchers, the EVX-B3 license signals pharma interest in computational biology beyond diagnostics.
Full story: https://getaibrief.com/story/merck-evaxion-ai-vaccine-discovery-validation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getaibrief.com/guides/methodology for the full editorial methodology.